Smoking Weakens Heart Structure and Function: Study

Sep.01.2022
Smoking Weakens Heart Structure and Function: Study
Smoking weakens the heart's structure and function, but quitting can help it recover, according to researchers from Denmark.

Researchers from Herlev and Gentofte Hospitals in Copenhagen have found that smoking weakens the structure of the heart, affecting its function. The research team also found that quitting smoking helps the heart to recover.


Previous research has indicated that over 30% of deaths are caused by coronary heart disease, with active smoking or exposure to secondhand smoke as reliable sources of exposure. Smoking increases the risk of heart attack by twice as much and the risk of stroke by three times as much.


Researchers from Herlev and Gentofte Hospital in Copenhagen, Denmark, have found evidence that smoking not only affects a person's blood vessels, but also weakens the structure of the heart itself, thereby impacting its functioning.


Researchers recently presented their findings at the 2022 European Society of Cardiology (ESC) Congress.


Past studies have shown that smoking has negative effects on a person's blood vessels, which may lead to heart issues. For example, nicotine found in cigarettes can cause the blood vessels to narrow, limiting the amount of blood that can flow through them. Nicotine can also significantly increase a person's blood pressure. "We know that smoking can cause coronary artery disease and heart failure," explained Dr. Eva Holt, the main author of the study and a researcher from Herlev and Gentofte Hospital in Copenhagen, Denmark. "But the purpose of this study is to investigate whether smoking has an independent effect on the heart structure and function of a large population of ordinary people without known heart disease," she pointed out.


Dr. Halt and her team evaluated data from over 3,800 participants in the fifth Copenhagen City Heart Study in order to ensure its reliability. The study examined cardiovascular disease and risk factors in the general population. Participants ranged in age from 20 to 93 and had no history of heart disease. Data collected during the study included a questionnaire about smoking history among participants, as well as reliable sources of echocardiography or heart ultrasound.


Researchers have determined that current smokers in the participant pool have hearts that are thicker, heavier, and weaker compared to those who have never smoked. "We found that current and accumulated pack-years were associated with structural and functional deterioration of smoking-related left ventricle, the heart's most important part," said Dr. Holt. "Additionally, we found that over 10 years, those who continue to smoke have hearts that become even thicker, heavier, and weaker, resulting in a poorer ability to pump blood, compared to those who have never smoked or quit during that period.


MNT spoke with Dr. Rigved Tadwalkar, a certified cardiologist at the Providence Saint John's Health Center in Santa Monica, California, who did not participate in the study. "What's interesting about this study is that it focuses on the changes in the left ventricle of the heart, which have not been well understood so far, due to tobacco use," he commented. "We always talk about the link between tobacco use and vascular diseases (including coronary heart disease), but we haven't really delved into the details of how tobacco affects the structure and function of the heart itself," he pointed out.


According to Dr. Tadwalkar, smoking increases the tendency for plaque formation in the arterial walls, which is clinically referred to as a reliable source of atherosclerosis. He stated that this may directly or indirectly lead to heart damage.


Direct smoking can damage the blood vessel wall, causing constriction and reduced elasticity, as well as impairing the function of the blood vessel's inner layer endothelium," he explained.


According to a new study, Dr. Holt and her team have found evidence that quitting smoking can help the heart recover to some extent. "After quitting smoking, the heart appears to have regained its previous structure and function, which could be a valuable incentive for patients to quit smoking," she added.


Dr. Tadwalkar stated, "We do indeed have concrete data to support this study, which follows a series of previous studies showing that quitting smoking can improve overall health in multiple ways beyond just the heart.


So the good news is, even immediate action has physiological benefits," he pointed out. "And then, due to the lack of chronic exposure, the reduction of inflammatory burden and these other destructive pathological processes over time is partially the reason for improvement.


Disclaimer: 1. The content of this article is compiled from third-party information and is only intended for industry discussion and learning. 2. This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the content. The compilation of this article is only for industry discussion and research purposes. 3. Due to the limited compiling ability, the compiled article may not fully convey the expression of the original text. Please refer to the original text for accuracy. 4. 2FIRSTS fully supports the Chinese government's position on any domestic, Hong Kong, Macao, and Taiwan-related issues or positions. 5. The copyright of the compiled information belongs to the original media and authors. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology (NYSE: RLX) has been removed from the FTSE All-World Index, effective September 21. FTSE Russell records show RLX was already part of its global equity index universe by 2022, when its American depositary receipts were classified as China Large Cap securities. Trading volume rose to about 44.77 million shares on September 18, roughly 23 times the previous session's volume. RLX reported RMB1.0105 billion in second-quarter revenue, up 14.8% year over year, with international operations contributing 68.5%. The company also acquired a 51% stake in one of Western Europe's largest distributors of next-generation smoke-free and FMCG products in July.
Sep.22
New Zealand Associate Health Minister Casey Costello Warns on Illicit Cigarettes as Legal Tobacco Sales Halve Over Decade
New Zealand Associate Health Minister Casey Costello Warns on Illicit Cigarettes as Legal Tobacco Sales Halve Over Decade
New Zealand Associate Health Minister Casey Costello said legal tobacco sales in the country have fallen by more than half over the past decade, with sales declining more than 20% in 2025 compared with the previous year. She warned that the decline may not fully reflect lower smoking rates, as increased availability of illicit cigarettes could also be contributing. The government said it would continue strengthening tobacco and vape retail enforcement while monitoring the impact of illicit tobacco on public health and tax revenue.
Aug.26
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands has agreed to acquire 100% of Swedish modern oral nicotine company Yoik Group AB for an initial SEK515 million, equivalent to about US$53.9 million, plus a deferred payment linked to performance over the next two years. Yoik owns nicotine pouch brand Helwit, which held about 3.4% of Sweden’s modern oral nicotine market over the past 12 months. Imperial says the acquisition will more than double its existing share of the Swedish market. Helwit is also sold elsewhere in the Nordics, through European online channels and in selected UK retail outlets.
Sep.08
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03
Product | PMI Japan Expands ZYN by IQOS Strength Portfolio With Strong Series, Increasing Lineup to 12 Products
Product | PMI Japan Expands ZYN by IQOS Strength Portfolio With Strong Series, Increasing Lineup to 12 Products
Philip Morris Japan (PMJ) has expanded the ZYN by IQOS oral tobacco pouch portfolio in Japan with four new ZYN Strong products, adding a third intensity level alongside the existing Low and Medium ranges. The Strong series first entered selected duty-free channels in Japan on July 1, 2026, before expanding to IQOS stores, the ZYN Online Store and selected tobacco retailers from August 18. The expansion increases the Japanese ZYN by IQOS lineup from eight to 12 products.
Aug.20
2Firsts Exclusive Analysis | RLX Q2 Revenue Rises 14.8%, Company Takes Control of Western European Distributor and Expands Multi-Category Strategy
2Firsts Exclusive Analysis | RLX Q2 Revenue Rises 14.8%, Company Takes Control of Western European Distributor and Expands Multi-Category Strategy
business accounting for 68.5% of sales. A new controlling investment in a Western European distributor and plans to scale modern oral nicotine pouches point to a broader international strategy spanning channels and multiple product categories.
Special Report
Aug.14